logo-loader
viewCytoDyn Inc.

CytoDyn presents 'stunning' data on treatment of HIV at Seattle conference

CytoDyn Inc (OTCQB:CYDY) CEO Dr. Nader Pourhassen and Dr. Richard Pestell tell Proactive Investors that Pourhassen presented data on its anti-HIV therapy at the Conference on Retroviruses and Opportunistic Infections in Seattle this week.

Highlights of the data include that patients had passed 12 weeks with close to 90% responders rate after the first induction period. And the company is ready to submit a pivotal trial to the FDA this month for final approval as a label expansion for mono-therapy.

Quick facts: CytoDyn Inc.

Price: 4.974 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2.58 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn addresses negative claims made by healthcare publication STAT on its...

CytoDyn (OTCQB:CYDY) CEO Nader Pourhassan spoke to Proactive, addressing negative claims made by healthcare publication STAT on its coronavirus study. Pourhassan says the company has released what he says are positive results from its coronavirus treatment clinical study, and explains why he...

2 days, 18 hours ago

2 min read